Iqvia Hldgs Inc Stock Price, News & Analysis

IQVIA Holdings Inc. (NYSE:IQV) has announced that its CFO, Ron Bruehlman, will be speaking at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024 at 10:00 a.m. ET in New York. This event presents an opportunity for investors and analysts to gain insights into IQVIA's financial strategies and market positioning.

The presentation will be accessible via a live audio webcast on IQVIA's Investor Relations website. For those unable to attend or listen live, a replay of the webcast will be made available later the same day, ensuring wide access to the information shared during the conference.

This appearance at a major healthcare conference underscores IQVIA's commitment to transparency and engagement with the investment community, potentially impacting investor sentiment and the company's stock performance.

IQVIA Holdings Inc. (NYSE:IQV) reported strong financial results for Q2 2024. Revenue increased 2.3% to $3,814 million, with a 3.5% growth at constant currency. GAAP Net Income reached $363 million, while Adjusted EBITDA was $887 million. The company's GAAP Diluted EPS was $1.97, and Adjusted Diluted EPS grew 8.6% to $2.64.

R&D Solutions showed robust performance with quarterly bookings of $2.7 billion and a book-to-bill ratio of 1.27x. The R&D Solutions contracted backlog grew 7.7% year-over-year to $30.6 billion. IQVIA updated its full-year 2024 guidance, projecting revenue between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted EPS between $11.10 and $11.30.

IQVIA (NYSE: IQV) has been named a Leader in the Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix Assessment 2024 by Everest Group. This recognition underscores IQVIA’s impact on the market and delivery effectiveness. The report emphasizes IQVIA's innovative approach and comprehensive solutions portfolio, which accelerates drug development and improves patient outcomes. Leveraging AI-enabled technology and a strong global presence, IQVIA addresses regulatory complexities and compliance demands. Their end-to-end solutions transform data into actionable insights, enhancing regulatory and medical decision-making. Key technologies include IQVIA RIM Smart and productivity tools for electronic submissions.

IQVIA Holdings (NYSE: IQV) will release its second-quarter 2024 financial results on July 22, 2024, before market open.

A conference call and webcast hosted by the management team will follow at 9:00 a.m. ET. The earnings release and financial information will be available on the IQVIA Investor Relations website. Registration is required to participate in the conference call, with details provided upon confirmation. A webcast replay will be accessible about two hours after the live event.

IQVIA's SmartSolve Enterprise Quality Management System (eQMS) has won the 'Best Use of Artificial Intelligence in Healthcare' award at the 2024 MedTech Breakthrough Awards.

SmartSolve eQMS is part of IQVIA's suite of safety, regulatory, and quality technologies, offering a centralized platform for quality compliance in the life sciences industry.

The system leverages AI to streamline quality processes, recommend appropriate codes for medical device adverse events, and support continuous improvement.

This award highlights IQVIA’s innovation in AI-powered healthcare solutions, with over 4,500 nominations received this year.

The MedTech Breakthrough Awards recognize excellence in global health and medical technology, emphasizing creativity, innovation, and success.

IQVIA (NYSE:IQV) has launched One Home for Sites™, a new technology platform designed to streamline and integrate the various systems and tasks required by clinical research sites. This platform acts as a single sign-on and dashboard, reducing the overload of multiple software applications, thereby freeing up time for site staff to focus on patient recruitment and treatment. One Home for Sites is currently in Beta testing and being piloted by IQVIA Prime Sites, with input from over 100 site personnel. The platform aims to enhance site productivity and accelerate the delivery of new treatments by acting as a neutral aggregator and communicator among various clinical applications.

The IQVIA Institute has released a report detailing the global rise in cancer diagnoses and the corresponding increase in innovative cancer therapies. Cancer incidence is projected to reach 32 million new cases annually by 2050, especially in lower-income countries.

Global spending on cancer medicines rose to $223 billion in 2023 and is expected to hit $409 billion by 2028. The year 2023 saw the launch of 25 novel active substances (NASs) in oncology, bringing the total to 193 since 2014.

Over 2,000 new oncology clinical trials began in 2023, featuring advanced therapies like cell and gene therapies, antibody-drug conjugates, and radioligand therapies. Despite advancements, geographic disparities in access to these therapies persist.

Oncology trials have become less complex, increasing the success rate to 10% in 2023 from 4% the previous year. However, the pace of bringing new therapies to patients remains uneven due to differences in healthcare infrastructure and adoption rates.

Overall spending on medicines in the U.S. grew by 2.5% in 2023, reaching $435 billion. Excluding COVID-19 vaccines and therapeutics, the growth rate was 9.9%, driven by advances in oncology, immunology, diabetes, and obesity treatments. Patient out-of-pocket costs rose to $91 billion, influenced by wider use of GLP-1 agonists for diabetes and obesity. New prescriptions increased by 4%, while patient visits and diagnostics fell by 4-6%. The flu vaccination rate dropped by 17%. The IQVIA Health Services Utilization Index fell 3% to 97. The report projects continued growth in medicine spending, driven by innovation but tempered by patent expirations and the introduction of biosimilars. Net pharmaceutical spending is forecasted to grow at 4-7% annually through 2028, with oncology and obesity as primary growth drivers.

IQVIA Holdings Inc. announced that Ron Bruehlman, CFO, will speak at the Bank of America Health Care Conference on May 14, 2024. The presentation will be webcasted live and available for replay on the IQVIA Investor Relations website.